Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 217,273,816 papers from all fields of science
Search
Sign In
Create Free Account
melanoma
Known as:
Malignant Melanomas
, melanocarcinoma
, Melanoma [Disease/Finding]
Expand
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
48 relations
AIM1 gene
AIM1 wt Allele
Absent in melanoma 1 protein
Aldesleukin
Expand
Narrower (5)
Cutaneous Melanoma
Epithelioid Cell Melanoma
Hutchinson's Melanotic Freckle
Nodular melanoma
Expand
Broader (2)
Neoplasms
melanocyte
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Wolchok
,
V. Chiarion-Sileni
,
+30 authors
J. Larkin
New England Journal of Medicine
2017
Corpus ID: 205102506
BACKGROUND Nivolumab combined with ipilimumab resulted in longer progression‐free survival and a higher objective response rate…
Expand
Highly Cited
2017
Highly Cited
2017
Dermatologist-level classification of skin cancer with deep neural networks
A. Esteva
,
Brett Kuprel
,
+4 authors
S. Thrun
Nature
2017
Corpus ID: 3767412
Skin cancer, the most common human malignancy, is primarily diagnosed visually, beginning with an initial clinical screening and…
Expand
Highly Cited
2015
Highly Cited
2015
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
M. Valsecchi
New England Journal of Medicine
2015
Corpus ID: 4905508
n engl j med 373;1 nejm.org july 2, 2015 23 The authors’ full names, academic de‐ grees, and affiliations are listed in the Ap…
Expand
Highly Cited
2013
Highly Cited
2013
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok
,
H. Kluger
,
+21 authors
M. Sznol
New England Journal of Medicine
2013
Corpus ID: 205095555
BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4…
Expand
Highly Cited
2012
Highly Cited
2012
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian
,
F. Hodi
,
+27 authors
M. Sznol
New England Journal of Medicine
2012
Corpus ID: 1358630
BACKGROUND Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We…
Expand
Highly Cited
2009
Highly Cited
2009
Final version of 2009 AJCC melanoma staging and classification.
C. Balch
,
J. Gershenwald
,
+17 authors
V. Sondak
Journal of Clinical Oncology
2009
Corpus ID: 22073158
PURPOSE To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on…
Expand
Review
2008
Review
2008
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
A. Renehan
,
M. Tyson
,
M. Egger
,
R. Heller
,
M. Zwahlen
The Lancet
2008
Corpus ID: 99121
Highly Cited
2005
Highly Cited
2005
Distinct sets of genetic alterations in melanoma.
J. Curtin
,
J. Fridlyand
,
+9 authors
B. Bastian
New England Journal of Medicine
2005
Corpus ID: 40468644
BACKGROUND Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and…
Expand
Highly Cited
2002
Highly Cited
2002
Mutations of the BRAF gene in human cancer
H. Davies
,
G. Bignell
,
+49 authors
P. Futreal
Nature
2002
Corpus ID: 3071547
Cancers arise owing to the accumulation of mutations in critical genes that alter normal programmes of cell proliferation…
Expand
Highly Cited
2001
Highly Cited
2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
C. Balch
,
S. Soong
,
+16 authors
A. Morabito
Journal of Clinical Oncology
2001
Corpus ID: 35350763
PURPOSE The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE